Protacs, which induce selective degradation of their target protein via the ubiquitin-proteasome system, are useful for the down-regulation of various proteins, including disease-related proteins and epigenetic proteins. Here is the latest research on protacs.

October 23, 2020
Open Access

First small-molecule PROTACs for G protein-coupled receptors: inducing α1A -adrenergic receptor degradation

Acta Pharmaceutica Sinica. B
Zhenzhen LiMinyong Li
October 28, 2020

RNA-PROTACs - degraders of RNA-binding proteins

Angewandte Chemie
Alice GhidiniJonathan Hall
September 16, 2020
Open Access

Degrading AR-Dependent Cancers: Expanding the Role of PROTACs

Neoplasia : an International Journal for Oncology Research
Anna R Michmerhuizen, Corey Speers
September 6, 2020
Comment / Editorial
Open Access

Could PROTACs Protect Us From COVID-19?

Drug Discovery Today
Wilnelly Martinez-Ortiz, Ming-Ming Zhou
October 2, 2020
Open Access

Targeted Protein Degradation as a Promising Tool for Epigenetic Upregulation of Fetal Hemoglobin

Thijs C J VerheulSjaak Philipsen
September 25, 2020
Open Access

Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC)

European Journal of Medicinal Chemistry
Fangyuan CaoFrank J Dekker
September 15, 2020
Open Access

Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors

Exploration of Targeted Anti-tumor Therapy
Rachael ArthurGraham Packham
September 29, 2020
Open Access

Targeting Cullin-RING E3 Ligases for Radiosensitization: From NEDDylation Inhibition to PROTACs

Frontiers in Oncology
Shuhua Zheng, Wensi Tao
September 15, 2020

Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of PARP1 for Treating Cancers

Journal of Medicinal Chemistry
Chao-Guo CaoYuanwei Chen
September 5, 2020

Discovery of potent small molecule PROTACs targeting mutant EGFR

European Journal of Medicinal Chemistry
Hong-Yi ZhaoSan-Qi Zhang
September 6, 2020

Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation

Cell Chemical Biology
Jing ZhangXuedong Dai
October 6, 2020

Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins

Journal of Medicinal Chemistry
Dan SindhikaraAndreas Evers
October 5, 2020
Open Access

Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer

Hidetomo YokooYosuke Demizu
September 3, 2020
Open Access

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

Acta Pharmaceutica Sinica. B
Yuan FangBin Yu
October 27, 2020

Charting a New Path Towards Degrading Every Protein

Chembiochem : a European Journal of Chemical Biology
Behnam Nabet
October 5, 2020
Open Access

Development of a Hematopoietic Prostaglandin D Synthase-Degradation Inducer

Hidetomo YokooYosuke Demizu
September 18, 2020
Open Access

Understanding and Improving the Membrane Permeability of VH032-Based PROTACs

ACS Medicinal Chemistry Letters
Victoria G KleinR Scott Lokey
September 27, 2020
Open Access

The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells

Cell Death & Disease
An-Cheng QinXing-Sheng Lu

Sign up to follow this feed and discover related papers.

Related Feeds


Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.


Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.


Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.


An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

© 2020 Meta ULC. All rights reserved